Novo Nordisk, the Danish drugmaker behind famed weight-loss drugs Wegovy and Ozempic, is leading the way in the semaglutide trend.
The drugs help people lose weight, but they've also proven to be helpful in reducing health conditions like heart disease and kidney disease.
CEO Mike Doustdar says more people are starting to recognise that Novo Nordisk's output goes beyond an agent that reduces sugar for diabetics.
"It has some very serious health benefits around it, be it cardiovascular protection, liver protection, kidney protection - and more to be tested. So it's a breakthrough innovation."
LISTEN ABOVE

Perspective with Heather du Plessis-Allan: The attention on the Waikato ED case could increase the odds of fixing the problem
02:06

Full Show Podcast: 03 July 2026
1:40:38

Perspective with Heather du Plessis-Allan: What real employer would do what the Ministry of Justice did?
02:25